SEC Form 4 · accession 0001209191-17-058699
Intra-Cellular Therapies, Inc. · ITCI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sharon Mates
Officer — Chairman, President & CEO · Director
Period of report
Oct 30, 2017
Accepted (ET)
Nov 1, 2017 · 8:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567514
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 30, 2017 | M | 18,750 | $1.50 | A | 1,107,457 | D | |
| Common StockF2 | Oct 30, 2017 | S | 18,750 | $15.75 | D | 1,088,707 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $1.50 | Oct 30, 2017 | M | 18,750 | D | — | Dec 12, 2017 | Common Stock | 0 | 0 | D |
Explanation of responses
- F1The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 1, 2017. The option was to expire on December 12, 2017. A majority of the proceeds from these sales will be used to cover the reporting person's tax liability arising from option exercises.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.51 to $16.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price.
- F3All shares underlying this option have vested.
Remarks
As previously disclosed in the Issuer's prospectus supplement filed with Securities and Exchange Commission on September 27, 2017, the lock-up agreement into which the reporting person entered in connection with the Issuer's public offering of common stock that closed in October 2017 permitted the reporting person to effect the transactions reported in this Form 4.